---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000058"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-10-17T23:59:59+00:00"
generated_at: "2026-05-30T13:12:16.728927+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability

## Summary
- HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.
- Suicidal ideation decreased 80% (from 12.5% to 2.6%) over 10 days.
- SPN-820 well-tolerated; discontinuation rate 2.5% due to AEs; common AEs: headache, nausea, somnolence, dizziness.
- Study enrolled 40 subjects; 38 completed 10-day treatment; open-label, adjunctive to baseline antidepressant.
- Phase 2b double-blind placebo-controlled study topline results expected first-half 2025.

## SEC filing metadata
- accession: 0001356576-24-000058
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000058/0001356576-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000058/supn-20241017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000058
- JSON: https://secwatch.observer/filing/0001356576-24-000058.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.